Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1985
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk ; volume:29 ; number:4 ; day:27 ; month:6 ; year:2022 ; pages:327-336 ; date:7.2022
High blood pressure & cardiovascular prevention ; 29, Heft 4 (27.6.2022), 327-336, 7.2022
- Urheber
-
Figorilli, Filippo
Mannarino, Massimo R.
Bianconi, Vanessa
Pirro, Matteo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40292-022-00529-2
- URN
-
urn:nbn:de:101:1-2022082923434262981401
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Figorilli, Filippo
- Mannarino, Massimo R.
- Bianconi, Vanessa
- Pirro, Matteo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cholesterol-Lowering Super juice
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
Cholesterol lowering: role in cancer prevention and treatment
Cholesterol lowering effect of a soy drink enriched with plant sterols in a French population with moderate hypercholesterolemia
Low-density lipoprotein cholesterol lowering treatment: the current approach
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis
Cholesterol-Lowering Super juice
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
Cholesterol lowering: role in cancer prevention and treatment
Cholesterol lowering effect of a soy drink enriched with plant sterols in a French population with moderate hypercholesterolemia
Low-density lipoprotein cholesterol lowering treatment: the current approach
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis
Cholesterol-Lowering Super juice
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
Cholesterol lowering: role in cancer prevention and treatment
Cholesterol lowering effect of a soy drink enriched with plant sterols in a French population with moderate hypercholesterolemia
Low-density lipoprotein cholesterol lowering treatment: the current approach
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?